Basic Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2021; 27(26): 4208-4220
Published online Jul 14, 2021. doi: 10.3748/wjg.v27.i26.4208
Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer
Xiu-Yan Li, Qing-Xia Guan, Yu-Zhou Shang, Yan-Hong Wang, Shao-Wa Lv, Zhi-Xin Yang, Rui Wang, Yu-Fei Feng, Wei-Nan Li, Yong-Ji Li
Xiu-Yan Li, Qing-Xia Guan, Yu-Zhou Shang, Yan-Hong Wang, Shao-Wa Lv, Zhi-Xin Yang, Rui Wang, Yu-Fei Feng, Wei-Nan Li, Yong-Ji Li, College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang Province, China
Author contributions: Li XY, Guan QX, Shang YZ, Wang YH, Lv SW, Yang ZX, Wang R, Feng YF, Li WN, and Li YJ performed the experiments and acquired and analyzed the data; Li XY, Guan QX, Shang YZ, and Wang YH wrote the manuscript; All authors approved the final version of the article.
Supported by National Natural Science Foundation of China, No. 82074025 and No. 82074271; the Heilongjiang Traditional Chinese Medicine Research Project, No. ZHY18-047; and Scientific Research Project of Heilongjiang Health Committee, No. 2020-293.
Institutional review board statement: This study was approved by Ethics Committee of Heilongjiang University of Chinese Medicine, Harbin, China.
Conflict-of-interest statement: The authors report no conflicts of interest in this work.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Ji Li, PhD, Professor, College of Pharmacy, Heilongjiang University of Chinese Medicine, No. 24 Heping Road, Xiangfang District, Harbin 150040, Heilongjiang Province, China. liyongji2009@163.com
Received: February 25, 2021
Peer-review started: February 25, 2021
First decision: April 18, 2021
Revised: April 27, 2021
Accepted: May 27, 2021
Article in press: May 27, 2021
Published online: July 14, 2021
Core Tip

Core Tip: Norcantharidin (NCTD) is suitable for the treatment of primary liver cancer, especially early and middle primary liver cancer. However, the side effects of NCTD have limited its application. Therefore, we established a liver-targeting therapy in which NCTD is loaded into IRMOF-3 coated with a thermosensitive gel, which can be efficiently delivered to liver cancer cells and slowly released. The results demonstrate that this thermosensitive gel-encapsulated IRMOF-3 has great advantages as an antitumor drug carrier and provides some ideas for passive targeting therapy of tumors.